LOC100039995 Inhibitors
LOC100039995, a protein subject to modulation by a diverse array of inhibitors, holds a pivotal role in cellular processes, acting as a nexus for various signaling pathways. While the precise functionalities of LOC100039995 are yet to be fully elucidated, its involvement in critical cellular responses positions it as a focal point for investigation. As a member of an emerging class of proteins, the intricate mechanisms underlying LOC100039995's functions remain an active area of scientific inquiry. The LOC100039995 inhibitors under scrutiny exhibit a range of mechanisms targeting essential cellular pathways. Trametinib and U0126, inhibitors of the mitogen-activated protein kinase (MAPK) pathway, present avenues for LOC100039995 modulation. By influencing downstream signaling cascades within the MAPK pathway, these inhibitors have the potential to intricately impact LOC100039995 and its involvement in cellular responses. Expanding the scope to TGF-beta signaling, SB431542 and CAY10603, TGF-beta receptor inhibitors, offer an indirect approach to LOC100039995 modulation. Given LOC100039995's participation in cellular responses to TGF-beta, these inhibitors disrupt TGF-beta signaling, indirectly influencing LOC100039995 and its role in mediating cellular processes associated with this pathway.
LY294002 and Wortmannin, inhibitors of the phosphoinositide 3-kinase (PI3K)/Akt pathway, introduce additional dimensions to LOC100039995 modulation. As integral components of intracellular signaling, these inhibitors interfere with crucial pathways, potentially modulating LOC100039995 through intricate signaling networks. GSK650394, a p38 MAPK inhibitor, further contributes to the array of MAPK pathway inhibitors influencing LOC100039995 through alterations in downstream signaling cascades. Additionally, SB216763, a GSK-3 inhibitor, introduces an indirect approach by targeting Wnt signaling, potentially modulating LOC100039995 through interference with Wnt-mediated pathways. In conclusion, this diverse array of LOC100039995 inhibitors offers a sophisticated toolkit for dissecting the regulation of LOC100039995, providing valuable insights into the intricate signaling networks and regulatory mechanisms associated with this enigmatic protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor targeting the MAPK pathway. Trametinib interferes with downstream signaling, potentially modulating LOC100039995 indirectly. The MAPK pathway regulates various cellular processes, and alterations induced by Trametinib may impact the expression or activity of LOC100039995 through intricate signaling networks. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-beta receptor inhibitor affecting TGF-beta signaling. SB431542 disrupts TGF-beta-mediated pathways, which can indirectly influence LOC100039995 given its involvement in cellular responses to TGF-beta. This inhibitor can potentially alter the downstream signaling cascades and cellular processes that contribute to the regulation of LOC100039995. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting the PI3K/Akt pathway. LY294002 interferes with a key signaling pathway, potentially modulating LOC100039995 indirectly. The PI3K/Akt pathway plays a crucial role in cell survival and proliferation, and alterations induced by LY294002 may impact LOC100039995 expression or activity through intricate cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor targeting the MAPK pathway. SP600125 disrupts JNK signaling, potentially modulating LOC100039995 indirectly. The MAPK pathway is interconnected with various cellular processes, and alterations induced by SP600125 may impact the expression or activity of LOC100039995 through complex signaling networks. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor affecting the PI3K/Akt pathway. Wortmannin interferes with intracellular signaling, potentially modulating LOC100039995 indirectly. The PI3K/Akt pathway is vital in cellular functions, and alterations induced by Wortmannin may impact the expression or activity of LOC100039995 through intricate signaling networks. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
LSD1 inhibitor targeting histone demethylation. SP2509 modulates epigenetic regulation, potentially influencing LOC100039995 indirectly. LSD1 is involved in chromatin remodeling, and alterations induced by SP2509 may impact the expression or activity of LOC100039995 through changes in the epigenetic landscape. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor targeting the MAPK pathway. PD98059 interferes with downstream signaling, potentially modulating LOC100039995 indirectly. The MAPK pathway regulates various cellular processes, and alterations induced by PD98059 may impact the expression or activity of LOC100039995 through intricate signaling networks. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
FGFR inhibitor affecting the FGF pathway. AG-879 disrupts FGFR signaling, potentially modulating LOC100039995 indirectly. The FGF pathway is interconnected with various cellular processes, and alterations induced by AG-879 may impact the expression or activity of LOC100039995 through complex signaling networks. | ||||||
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $183.00 $754.00 | 8 | |
p38 MAPK inhibitor targeting the MAPK pathway. GSK650394 interferes with downstream signaling, potentially modulating LOC100039995 indirectly. The MAPK pathway regulates diverse cellular processes, and alterations induced by GSK650394 may impact the expression or activity of LOC100039995 through complex signaling networks. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
GSK-3 inhibitor affecting Wnt signaling. SB216763 disrupts Wnt-mediated pathways, potentially modulating LOC100039995 indirectly. The Wnt pathway is interconnected with various cellular processes, and alterations induced by SB216763 may impact the expression or activity of LOC100039995 through intricate signaling networks. | ||||||